import Navbar from '@/components/Navbar';
import Footer from '@/components/Footer';
import { Link } from 'react-router-dom';
import { SEOHead } from '@/components/seo/SEOHead';
import { BreadcrumbNav } from '@/components/seo/BreadcrumbNav';
import { FAQSection } from '@/components/healthcare-research/FAQSection';
import { buildBreadcrumbSchema } from '@/lib/seo/schemas';
import { getStandaloneReportConfig } from '@/data/reportConversionConfig';
import { MarketIntelligenceSections } from '@/components/market-intelligence';
import { buildReportEnrichmentSchemas } from '@/lib/reportEnrichmentSchemas';
import {
  ReportConsultationBand,
  ReportContentWithAside,
  ReportMidPageCta,
  ReportReadingProgress,
} from '@/components/report-conversion';
import { ReportPremiumHero } from '@/components/report-premium';
import { finalizeStandaloneHealthcareFaqs } from '@/data/standaloneCountryReportContent';

const breadcrumbItems = [
  { name: 'Home', href: '/' },
  { name: 'USA Healthcare Market Report', href: '/usa-healthcare-market-report' },
];

const REPORT_FAQ_ITEMS = finalizeStandaloneHealthcareFaqs([
  {
    question: 'How big is the USA healthcare market in 2026?',
    answer: 'The United States healthcare market is the world\'s largest, estimated at USD 4.4–4.6 trillion in 2026, representing approximately 17.6% of GDP. The US healthcare system combines public payers (Medicare for adults 65+, Medicaid for low-income populations, managed by CMS — Centers for Medicare & Medicaid Services) and private insurance (employer-sponsored insurance, ACA marketplace plans, and commercial managed care plans). CMS administers approximately USD 1.8 trillion in annual expenditure. Approximately 92% of the population has some form of health insurance coverage.',
  },
  {
    question: 'What is the USA pharmaceutical market size in 2026?',
    answer: 'The US pharmaceutical market is estimated at USD 590–640 billion in 2026 — the world\'s largest by value, accounting for approximately 45% of global pharmaceutical sales. FDA approves new molecular entities through the NDA (New Drug Application) and BLA (Biologics License Application) pathways, with priority review, breakthrough therapy, accelerated approval, and fast track designations available for qualifying products. PBMs (pharmacy benefit managers — UnitedHealth/Optum, CVS/Caremark, Express Scripts/Cigna) manage formulary placement and rebate negotiations for the majority of commercial and Medicare Part D plans. The Inflation Reduction Act (IRA) of 2022 introduced Medicare drug price negotiation for high-expenditure products — the first federal drug price negotiation in US history.',
  },
  {
    question: 'How does FDA drug approval and market access work in the USA?',
    answer: 'FDA approval grants market authorisation but does not guarantee commercial access. After FDA approval: (1) Formulary placement negotiations with PBMs (for commercial market) and CMS (for Medicare Part D) determine coverage and out-of-pocket cost; (2) Medicare Part B (physician-administered infusions) uses ASP (Average Sales Price) plus 6% reimbursement; (3) GPO (Group Purchasing Organization) contracts with Premier, Vizient, or HealthTrust determine hospital supply chain pricing; (4) ICER (Institute for Clinical and Economic Review) cost-effectiveness assessments influence payer decisions, though ICER has no statutory authority. The US has no single national HTA body — payer-by-payer formulary negotiations are the primary access mechanism.',
  },
  {
    question: 'What are the largest therapy areas in the USA pharmaceutical market?',
    answer: 'The five largest US pharmaceutical therapy areas by commercial spend are: oncology (largest and fastest-growing; immuno-oncology, targeted therapy, and CAR-T therapies driving growth); immunology and biologics (TNF inhibitors at scale; IL-17/23 and JAK inhibitors growing; biosimilars accelerating since 2023); GLP-1/obesity and diabetes (semaglutide and tirzepatide driving unprecedented category growth; potential USD 50B+ market by 2030); cardiovascular (novel heart failure agents, PCSK9 inhibitors, novel anticoagulants); and rare disease and gene therapy (orphan drug designations, gene therapies receiving USD 1M+ list prices for one-time treatments). Mental health and CNS are growing rapidly.',
  },
  {
    question: 'What is the Inflation Reduction Act (IRA) impact on the US pharmaceutical market?',
    answer: 'The Inflation Reduction Act of 2022 introduced three significant changes to US pharmaceutical pricing: (1) Medicare drug price negotiation — CMS can negotiate prices directly for the highest-spend Medicare drugs (10 drugs in 2026, expanding to 15 in 2027 and 20 per year thereafter); (2) Inflation rebates — manufacturers must pay rebates if price increases exceed CPI; (3) Out-of-pocket cap — Medicare Part D beneficiary OOP costs capped at USD 2,000 per year from 2025. The negotiated prices (MFPs — Maximum Fair Prices) took effect January 2026 for the first cohort of 10 drugs, representing an average 60–80% reduction from list price. The IRA is reshaping commercial strategy for products with significant Medicare exposure, particularly in the cardiovascular, diabetes, and oncology categories.',
  },
  {
    question: 'How does BioNixus serve US-based pharmaceutical companies expanding to MENA?',
    answer: 'BioNixus supports US-headquartered pharmaceutical and medical device companies expanding into GCC and MENA markets. From our London office, we provide SFDA (Saudi Arabia), MOHAP (UAE), and GCC-wide regulatory pathway intelligence; NUPCO tender intelligence and hospital formulary data; physician panel surveys across all major therapeutic areas in Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, and Egypt; and comparative US vs. GCC market intelligence for global commercial and market access strategy. BioNixus delivers the regional granularity that US commercial teams need to prioritise, plan, and execute GCC market entry.',
  },
], 'usa');

const REPORT_CONVERSION = getStandaloneReportConfig('/usa-healthcare-market-report');
const FAQ_SECTION_ID = 'usa-healthcare-market-faq';

const jsonLd = [
  buildBreadcrumbSchema(breadcrumbItems),
  {
    '@context': 'https://schema.org',
    '@type': 'Article',
    headline: 'USA Healthcare Market Report 2026: FDA, CMS, PBMs, and Pharmaceutical Market Intelligence',
    author: { '@type': 'Organization', name: 'BioNixus' },
    publisher: { '@type': 'Organization', name: 'BioNixus', logo: { '@type': 'ImageObject', url: 'https://www.bionixus.com/bionixus-logo.webp' } },
    datePublished: '2026-05-27',
    dateModified: '2026-05-27',
    mainEntityOfPage: 'https://www.bionixus.com/usa-healthcare-market-report',
  },
  {
    '@context': 'https://schema.org',
    '@type': 'FAQPage',
    url: `https://www.bionixus.com/usa-healthcare-market-report#${FAQ_SECTION_ID}`,
    mainEntity: REPORT_FAQ_ITEMS.map((item) => ({ '@type': 'Question', name: item.question, acceptedAnswer: { '@type': 'Answer', text: item.answer } })),
  },
  ...buildReportEnrichmentSchemas({
    pageTitle: "USA Healthcare Market Report 2026 | FDA, CMS, PBMs & Pharmaceutical Market Intelligence | BioNixus",
    pageMetaDescription: "USA healthcare market at USD 4.5 trillion in 2026 — world's largest. FDA approval pathways, Medicare IRA drug negotiations, PBM formulary access, USD 600B pharmaceutical market, and BioNixus GCC expansion intelligence.",
    countryName: "United States",
    marketSlug: "usa",
    publishedDate: "2026-05-27",
    modifiedDate: "2026-05-27",
  })
];

const UsaHealthcareMarketReport = () => (
  <div className="min-h-screen bg-background">
    <Navbar />
    <SEOHead
      title="USA Healthcare Market Research Report 2026 | BioNixus"
      description="USA healthcare market research: USD 4.5T healthcare market, FDA approval pathways, Medicare, PBMs, USD 600B pharmaceutical market — BioNixus global pharma."
      canonical="https://www.bionixus.com/usa-healthcare-market-report"
      jsonLd={jsonLd}
    />
      <ReportReadingProgress progressId="report-rp-usa-healthcare-market-report" />
      <main>
      <div className="section-padding pt-24 pb-4"><div className="container-wide"><BreadcrumbNav items={breadcrumbItems} /></div></div>
              <ReportPremiumHero
          title="USA Healthcare Market Report 2026: FDA Approval, Medicare IRA Negotiations, and Commercial Market Intelligence"
          description="The USA healthcare market is the world's largest, estimated at USD 4.4–4.6 trillion in 2026, with a pharmaceutical market of roughly USD 590–640 billion. BioNixus serves US-headquartered pharmaceutical and medical device companies with GCC and MENA market entry intelligence — delivering the regional granularity that American commercial teams need to prioritise and execute international expansion."
          config={REPORT_CONVERSION}
          marketSlug="usa"
          countryName="USA"
          stats={[
            { value: '~$4.5T', label: 'USA healthcare market 2026' },
            { value: '~$615B', label: 'Pharmaceutical market 2026' },
            { value: '~$180B', label: 'Medical devices market 2026' },
          ]}
        />
      <ReportContentWithAside config={REPORT_CONVERSION}>
        <section className="section-padding bg-cream-dark" id="executive-summary">
        <div className="container-wide max-w-4xl mx-auto">
          <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">Executive Summary</h2>
          <div className="bg-white rounded-xl border border-border p-6 shadow-sm mb-6">
            <div className="grid sm:grid-cols-3 gap-6 text-center">
              <div><p className="text-3xl font-display font-bold text-primary">~$4.5T</p><p className="text-xs text-muted-foreground mt-1">USA healthcare market 2026</p></div>
              <div><p className="text-3xl font-display font-bold text-primary">~$615B</p><p className="text-xs text-muted-foreground mt-1">Pharmaceutical market 2026</p></div>
              <div><p className="text-3xl font-display font-bold text-primary">~$180B</p><p className="text-xs text-muted-foreground mt-1">Medical devices market 2026</p></div>
            </div>
          </div>
          <p className="text-muted-foreground leading-relaxed mb-4">The United States is the world's largest and most commercially significant healthcare market, accounting for approximately 45% of global pharmaceutical revenues. The Inflation Reduction Act drug price negotiations represent the most significant structural change to US pharmaceutical commercial models since the Medicare Modernization Act of 2003 — reshaping launch strategy, pricing architecture, and international reference pricing dynamics for all global pharmaceutical companies.</p>
          <p className="text-muted-foreground leading-relaxed">For GCC/MENA intelligence, see our <Link to="/gcc-pharma-market-report-2026" className="text-primary hover:underline font-medium">GCC Pharmaceutical Market Report 2026</Link>.</p>
        </div>
      </section>
              <MarketIntelligenceSections marketSlug="usa" countryName="USA" variant="healthcare" />

        <section className="section-padding" id="related-intelligence">
          <div className="container-wide max-w-4xl mx-auto">
            <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">Related BioNixus market intelligence</h2>
            <p className="text-muted-foreground leading-relaxed">
              BioNixus runs healthcare and pharmaceutical market research across the Americas. Benchmark USA against our{' '}
              <Link to="/canada-healthcare-market-report" className="text-primary hover:underline font-medium">Canada healthcare market report</Link>{' '}and{' '}
              <Link to="/brazil-healthcare-market-report" className="text-primary hover:underline font-medium">Brazil healthcare market report</Link>, or start from the{' '}
              <Link to="/healthcare-market-research" className="text-primary hover:underline font-medium">global healthcare market research hub</Link>{' '}and our{' '}
              <Link to="/market-research-healthcare" className="text-primary hover:underline font-medium">healthcare market research services</Link>. For therapy-segmented demand and access analysis, see our{' '}
              <Link to="/pharmaceutical-therapy-areas" className="text-primary hover:underline font-medium">pharmaceutical therapy-area coverage</Link>.
            </p>
            <ReportMidPageCta config={REPORT_CONVERSION} className="mt-8" />
          </div>
        </section>

        <FAQSection sectionId={FAQ_SECTION_ID} title="USA healthcare market 2026 — FDA, CMS, IRA, PBMs, and commercial market access FAQ" items={REPORT_FAQ_ITEMS} className="bg-muted/30" />        </ReportContentWithAside>
      <ReportConsultationBand config={REPORT_CONVERSION} />
        </main>
    <Footer />
  </div>
);

export default UsaHealthcareMarketReport;
